CRL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Charles River Laboratories International Inc (CRL) is not a strong buy for a beginner investor with a long-term strategy at the moment. While the stock shows some positive technical indicators and analysts maintain mixed ratings, the lack of significant positive catalysts, insider selling, and a recent decline in revenue make it prudent to hold off on investing for now.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 59.898, and moving averages are converging, suggesting no clear trend. The stock is trading near a resistance level (R1: 173.151), with the next resistance at 180.031.
The MACD indicates bullish momentum, and gross margin and EPS have shown YoY improvement in the latest quarter.
Insider selling has increased significantly (125.30% in the last month). Revenue declined YoY by -0.83%. Analysts have lowered price targets recently, citing slower organic growth and lower free cash flow. No recent news or significant positive catalysts.
In Q4 2025, revenue dropped by -0.83% YoY to $994.23M. However, net income improved by 28.21% YoY to -$276.56M, and EPS increased by 33.18% YoY to -5.62. Gross margin improved to 30.96%, up 11.49% YoY.
Analysts have mixed ratings. UBS and Mizuho maintain Neutral ratings with price targets of $175, citing slower growth and lower free cash flow. TD Cowen, Evercore ISI, and Barclays maintain Buy or Outperform ratings, but all have lowered price targets recently, reflecting concerns about the company's growth outlook.
